The latest American Society of Clinical Oncology/College of American Pathologists guidelines support reporting of HER2 status as positive for tumors if at least 10% of the cancer cells stain positive for HER2 by immunohistochemistry (8). This evidence concerns the gene ERBB2 and cancer.